Literature DB >> 29748007

Added prognostic value of CT characteristics and IASLC/ATS/ERS histologic subtype in surgically resected lung adenocarcinomas.

Young Joo Suh1, Hyun-Ju Lee2, Young Tae Kim3, Chang Hyun Kang3, In Kyu Park3, Yoon Kyung Jeon4, Doo Hyun Chung4.   

Abstract

OBJECTIVES: Our study investigates the added value of computed tomography (CT) characteristics, histologic subtype classification of the International Association for the Study of Lung Cancer (IASLC)/the American Thoracic Society (ATS)/the European Respiratory Society (ERS), and genetic mutation for predicting postoperative prognoses of patients who received curative surgical resections for lung adenocarcinoma.
MATERIALS AND METHODS: We retrospectively enrolled 988 patients who underwent curative resection for invasive lung adenocarcinoma between October 2007 and December 2013. Cox's proportional hazard model was used to explore the risk of recurrence-free survival, based on the combination of conventional prognostic factors, CT characteristics, IASLC/ATS/ERS histologic subtype, and epidermal growth factor receptor (EGFR) mutations. Incremental prognostic values of CT characteristics, histologic subtype, and EGFR mutations over conventional risk factors were measured by C-statistics.
RESULTS: During median follow-up period of 44.7 months (25th to 75th percentile 24.6-59.7 months), postoperative recurrence occurred in 248 patients (25.1%). In univariate Cox proportion hazard model, female sex, tumor size and stage, CT characteristics, and predominant histologic subtype were associated with tumor recurrence (P < 0.05). In multivariate Cox regression model adjusted for tumor size and stage, both CT characteristics and histologic subtype were independent tumor recurrence predictors (P < 0.05). Cox proportion hazard models combining CT characteristics or histologic subtype with size and tumor stage showed higher C-indices (0.763 and 0.767, respectively) than size and stage-only models (C-index 0.759, P > 0.05).
CONCLUSION: CT characteristics and histologic subtype have relatively limited added prognostic values over tumor size and stage in surgically resected lung adenocarcinomas.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CT characteristics; EGFR mutation; Histologic subtype; Lung adenocarcinoma; Prognosis

Mesh:

Year:  2018        PMID: 29748007     DOI: 10.1016/j.lungcan.2018.04.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  5 in total

1.  Lymph node micrometastasis in N stage: a call for more evidence.

Authors:  Yijiu Ren; Chenyang Dai; Huikang Xie; Yunlang She; Hang Su; Chang Chen
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.

Authors:  Hyungjin Kim; Hyun-Ju Lee; Hyunsook Hong; Young Jae Kim; Kwang Gi Kim; Yoon Kyung Jeon; Young Tae Kim
Journal:  Thorac Cancer       Date:  2019-06-18       Impact factor: 3.500

3.  Biomarker Potential of Preoperative Tumor Size in Determination of the Lymphovascular Invasion in Squamous Cell Lung Cancer and Lung Adenocarcinoma.

Authors:  Kemal Grbic; Aida Mujakovic; Orhan Lepara; Zahid Lepara; Edin Begic; Ferid Krupic
Journal:  Int J Appl Basic Med Res       Date:  2021-04-08

4.  Volume and Mass Doubling Time of Lung Adenocarcinoma according to WHO Histologic Classification.

Authors:  Jung Hee Hong; Samina Park; Hyungjin Kim; Jin Mo Goo; In Kyu Park; Chang Hyun Kang; Young Tae Kim; Soon Ho Yoon
Journal:  Korean J Radiol       Date:  2020-10-30       Impact factor: 3.500

5.  Machine-Learning-Derived Nomogram Based on 3D Radiomic Features and Clinical Factors Predicts Progression-Free Survival in Lung Adenocarcinoma.

Authors:  Guixue Liu; Zhihan Xu; Yaping Zhang; Beibei Jiang; Lu Zhang; Lingyun Wang; Geertruida H de Bock; Rozemarijn Vliegenthart; Xueqian Xie
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.